Cargando…

The Recurrent Urinary Tract Infection Symptom Scale: Development and validation of a patient‐reported outcome measure

OBJECTIVES: This study aimed to develop and validate a tailored patient‐reported outcome measure (PROM) evaluating the patient experience of recurrent urinary tract infection (rUTI) symptom severity. This measure was designed to supplement clinical testing methods, allowing full assessment of the pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Newlands, Abigail F., Roberts, Lindsey, Maxwell, Kayleigh, Kramer, Melissa, Price, Jessica L., Finlay, Katherine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071086/
https://www.ncbi.nlm.nih.gov/pubmed/37025478
http://dx.doi.org/10.1002/bco2.222
_version_ 1785019126400417792
author Newlands, Abigail F.
Roberts, Lindsey
Maxwell, Kayleigh
Kramer, Melissa
Price, Jessica L.
Finlay, Katherine A.
author_facet Newlands, Abigail F.
Roberts, Lindsey
Maxwell, Kayleigh
Kramer, Melissa
Price, Jessica L.
Finlay, Katherine A.
author_sort Newlands, Abigail F.
collection PubMed
description OBJECTIVES: This study aimed to develop and validate a tailored patient‐reported outcome measure (PROM) evaluating the patient experience of recurrent urinary tract infection (rUTI) symptom severity. This measure was designed to supplement clinical testing methods, allowing full assessment of the patient experience of rUTI symptom burden, while enhancing patient‐centred UTI management and monitoring. SUBJECTS AND METHODS: The Recurrent Urinary Tract Infection Symptom Scale (RUTISS) was developed and validated using a three‐stage methodology, in accordance with gold‐standard recommendations. Firstly, a two‐round Delphi study was conducted to gain insights from 15 international expert clinicians working in rUTI, developing an initial pool of novel questionnaire items, assessing content validity and making item refinements. Next, two phases of one‐to‐one semi‐structured cognitive interviews were conducted with a diverse sample of 28 people experiencing rUTI to assess questionnaire comprehensiveness and comprehensibility, making refinements after each phase. Finally, a comprehensive pilot of the RUTISS was conducted with 240 people experiencing rUTI across 24 countries, providing data for psychometric testing and item reduction. RESULTS: Exploratory factor analysis indicated a four‐factor structure comprising: ‘urinary pain and discomfort’, ‘urinary urgency’, ‘bodily sensations’ and ‘urinary presentation’, together accounting for 75.4% of the total variance in data. Qualitative feedback from expert clinicians and patients indicated strong content validity for items, which was supported by high content validity indices in the Delphi study (I‐CVI > 0.75). Internal consistency and test–retest reliability of the RUTISS subscales were excellent (Cronbach's α = 0.87–0.94 and ICC = 0.73–0.82, respectively), and construct validity was strong (Spearman's ρ = 0.60–0.82). CONCLUSION: The RUTISS is a 28‐item questionnaire with excellent reliability and validity, which dynamically assesses patient‐reported rUTI symptoms and pain. This new PROM offers a unique opportunity to critically inform and strategically enhance the quality of rUTI management, patient‐clinician interactions, and shared‐decision making by monitoring key patient‐reported outcomes.
format Online
Article
Text
id pubmed-10071086
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100710862023-04-05 The Recurrent Urinary Tract Infection Symptom Scale: Development and validation of a patient‐reported outcome measure Newlands, Abigail F. Roberts, Lindsey Maxwell, Kayleigh Kramer, Melissa Price, Jessica L. Finlay, Katherine A. BJUI Compass Original Articles OBJECTIVES: This study aimed to develop and validate a tailored patient‐reported outcome measure (PROM) evaluating the patient experience of recurrent urinary tract infection (rUTI) symptom severity. This measure was designed to supplement clinical testing methods, allowing full assessment of the patient experience of rUTI symptom burden, while enhancing patient‐centred UTI management and monitoring. SUBJECTS AND METHODS: The Recurrent Urinary Tract Infection Symptom Scale (RUTISS) was developed and validated using a three‐stage methodology, in accordance with gold‐standard recommendations. Firstly, a two‐round Delphi study was conducted to gain insights from 15 international expert clinicians working in rUTI, developing an initial pool of novel questionnaire items, assessing content validity and making item refinements. Next, two phases of one‐to‐one semi‐structured cognitive interviews were conducted with a diverse sample of 28 people experiencing rUTI to assess questionnaire comprehensiveness and comprehensibility, making refinements after each phase. Finally, a comprehensive pilot of the RUTISS was conducted with 240 people experiencing rUTI across 24 countries, providing data for psychometric testing and item reduction. RESULTS: Exploratory factor analysis indicated a four‐factor structure comprising: ‘urinary pain and discomfort’, ‘urinary urgency’, ‘bodily sensations’ and ‘urinary presentation’, together accounting for 75.4% of the total variance in data. Qualitative feedback from expert clinicians and patients indicated strong content validity for items, which was supported by high content validity indices in the Delphi study (I‐CVI > 0.75). Internal consistency and test–retest reliability of the RUTISS subscales were excellent (Cronbach's α = 0.87–0.94 and ICC = 0.73–0.82, respectively), and construct validity was strong (Spearman's ρ = 0.60–0.82). CONCLUSION: The RUTISS is a 28‐item questionnaire with excellent reliability and validity, which dynamically assesses patient‐reported rUTI symptoms and pain. This new PROM offers a unique opportunity to critically inform and strategically enhance the quality of rUTI management, patient‐clinician interactions, and shared‐decision making by monitoring key patient‐reported outcomes. John Wiley and Sons Inc. 2023-01-17 /pmc/articles/PMC10071086/ /pubmed/37025478 http://dx.doi.org/10.1002/bco2.222 Text en © 2023 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Newlands, Abigail F.
Roberts, Lindsey
Maxwell, Kayleigh
Kramer, Melissa
Price, Jessica L.
Finlay, Katherine A.
The Recurrent Urinary Tract Infection Symptom Scale: Development and validation of a patient‐reported outcome measure
title The Recurrent Urinary Tract Infection Symptom Scale: Development and validation of a patient‐reported outcome measure
title_full The Recurrent Urinary Tract Infection Symptom Scale: Development and validation of a patient‐reported outcome measure
title_fullStr The Recurrent Urinary Tract Infection Symptom Scale: Development and validation of a patient‐reported outcome measure
title_full_unstemmed The Recurrent Urinary Tract Infection Symptom Scale: Development and validation of a patient‐reported outcome measure
title_short The Recurrent Urinary Tract Infection Symptom Scale: Development and validation of a patient‐reported outcome measure
title_sort recurrent urinary tract infection symptom scale: development and validation of a patient‐reported outcome measure
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071086/
https://www.ncbi.nlm.nih.gov/pubmed/37025478
http://dx.doi.org/10.1002/bco2.222
work_keys_str_mv AT newlandsabigailf therecurrenturinarytractinfectionsymptomscaledevelopmentandvalidationofapatientreportedoutcomemeasure
AT robertslindsey therecurrenturinarytractinfectionsymptomscaledevelopmentandvalidationofapatientreportedoutcomemeasure
AT maxwellkayleigh therecurrenturinarytractinfectionsymptomscaledevelopmentandvalidationofapatientreportedoutcomemeasure
AT kramermelissa therecurrenturinarytractinfectionsymptomscaledevelopmentandvalidationofapatientreportedoutcomemeasure
AT pricejessical therecurrenturinarytractinfectionsymptomscaledevelopmentandvalidationofapatientreportedoutcomemeasure
AT finlaykatherinea therecurrenturinarytractinfectionsymptomscaledevelopmentandvalidationofapatientreportedoutcomemeasure
AT newlandsabigailf recurrenturinarytractinfectionsymptomscaledevelopmentandvalidationofapatientreportedoutcomemeasure
AT robertslindsey recurrenturinarytractinfectionsymptomscaledevelopmentandvalidationofapatientreportedoutcomemeasure
AT maxwellkayleigh recurrenturinarytractinfectionsymptomscaledevelopmentandvalidationofapatientreportedoutcomemeasure
AT kramermelissa recurrenturinarytractinfectionsymptomscaledevelopmentandvalidationofapatientreportedoutcomemeasure
AT pricejessical recurrenturinarytractinfectionsymptomscaledevelopmentandvalidationofapatientreportedoutcomemeasure
AT finlaykatherinea recurrenturinarytractinfectionsymptomscaledevelopmentandvalidationofapatientreportedoutcomemeasure